MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostate Cancer Prostatic Diseases Prostatic Neoplasms Skin Diseases Skin and Connective Tissue Diseases Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Center who have had at least 3 prior medical oncology visits.

Exclusion criteria

Patient is enrolled on a therapeutic clinical trial.
Patients whose primary language is not currently supported by Epic.

Treatment and study plan

Usual practice pattern (UPP)

Other

Patient follows usual practice pattern for routine care

Experimental: Enhanced Telehealth (ET)

Other

Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications

Primary outcomes

Proportion of routine face to face medical oncology related visits out of total medical oncology related visits

Time frame: 12 months

all patients who meet eligibility criteria and have completed at least 2 medical oncology visits during the 12 month follow up period will be included for endpoint evaluability during analyses

Study contacts

Contact information is provided by the study sponsor or research team.

Deborah Schrag, MD, MPH

CONTACT

212-639-5851

Erin Bange, MD, MSCE

CONTACT

[email protected]

646-422-4680

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: May 1, 2025
Registry last updated: Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting